EPAD
European Prevention of
Alzheimer's Dementia Consortium

Valuable and incredible resource offering open data access for the global Alzheimer's disease research community

The EPAD dataset

It includes cognitive (RBANS, MMSE, CDR), clinical (medical history, medications), biomarker (APOE, [CSF] Aβ42, tau), genomic, neuroimaging and lifestyle risk factor (sleep, diet, traumatic life events) information. In the future, the dataset will be enhanced with additional data.

The samples

Samples may also be accessed for use in Alzheimer's disease prevention research. We have more than 180,000 blood, CSF, saliva and urine samples collected from 3,000 participants at annual visits in the 4-year longitudinal EPAD study, and the ongoing Prevent Dementia and EPAD Scotland studies.

Assets

❖ Recruitment from Parent Cohorts across Europe
❖ Large and diverse population, covering the entire continuum of anticipated probability for Alzheimer's dementia development
❖ Wide-range of outcomes at each annual visit.

What is EPAD?

The European Prevention of Alzheimer's Dementia (EPAD) Consortium was an interdisciplinary research initiative spanning public and private sector organisations across Europe, running until 30 September 2020. EPAD was funded for five and a half years by the Innovative Medicines Initiative (now known as the Innovative Health Initiative) in conjunction with 39 partner organisations. Its aim was to improve the understanding of the early stages of Alzheimer's disease and deliver new preventative treatments.

One of the EPAD project's key achievements was the Longitudinal Cohort Study (LCS). It screened over 2,000 participants across 30 European study centres and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further understanding of the early stages of Alzheimer's disease.

EPAD has made this incredibly rich dataset open access and publicly available to the research community, through its partnership with the Alzheimer's Disease Data Initiative (ADDI), a non-profit organisation dedicated to fostering greater access to data and enabling researchers worldwide to accelerate the development of new and more effective treatments and cures for Alzheimer's disease and related dementias.

How to access the data?

The EPAD dataset is available on the AD Workbench, ADDI's secure, cloud-based platform that researchers around the world can access at no cost. Researchers simply create an AD Workbench account, request access to the data or images, and once approved by the EPAD team, can then access them on the AD Workbench (https://www.alzheimersdata.org/ad-workbench).

How to access the samples?

We will support you through every stage of the application process. Contact the Principal Investigator of the EPAD Bioresource and Chair of the Sample Access Committee Prof. Jean Manson (jean.manson@roslin.ed.ac.uk) for an initial informal discussion about the scope of your research and the range of samples that we can offer.